NCT05960721View on ClinicalTrials.gov

Low-dose NOAC Versus GDMT After LAAO

NARecruitingINTERVENTIONAL

Enrollment

4,220

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2028

Conditions

Atrial Fibrillation

Interventions

DRUG

Rivaroxaban 15mg

QD

DRUG

Aspirin 100mg

QD

DRUG

Clopidogrel 75mg

QD

DRUG

Rivaroxaban 10mg

QD

DRUG

Rivaroxaban 2.5mg

B.I.D

Trial Locations (1)

710032

RECRUITING

Ling Tao, Xi'an

All Listed Sponsors

lead

Xijing Hospital

OTHER